Trade

with

Oragenics Inc
(Amex: OGEN)
AdChoices
0.9400
-0.0100
-1.05%
After Hours :
-
-
-

Open

0.9500

Previous Close

0.9500

Volume (Avg)

29.34k (16.63k)

Day's Range

0.9400-0.9500

52Wk Range

0.8936-4.65

Market Cap.

34.37M

Dividend Rate ( Yield )

-

Beta

1.25

Shares Outstanding

36.18M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 1.03M

    • Net Income

    • -16.07M

    • Market Cap.

    • 34.37M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,321.20

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.25

    • Forward P/E

    • -

    • Price/Sales

    • 26.04

    • Price/Book Value

    • 2.74

    • Price/Cash flow

    • -4.87

      • EBITDA

      • -15.97M

      • Return on Capital %

      • -156.22

      • Return on Equity %

      • -174.77

      • Return on Assets %

      • -156.22

      • Book Value/Share

      • 0.35

      • Shares Outstanding

      • 36.18M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 5.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 81.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 34.61

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 67.00

            • 82.75

            • Pre-Tax Margin

            • -1,321.20

            • 39.38

            • Net Profit Margin

            • -1,321.20

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 49.40

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -916.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -905.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 17.10

              • 2.92

              • Quick Ratio

              • 16.61

              • 2.35

              • Interest Coverage

              • -920.67

              • 38.02

              • Leverage Ratio

              • 1.06

              • 2.21

              • Book Value/Share

              • 0.35

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.97

                • 243.90

                • P/E Ratio 5-Year High

                • -42.36

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.56

                • 124.82

                • Price/Sales Ratio

                • 26.04

                • 9.29

                • Price/Book Value

                • 2.74

                • 8.39

                • Price/Cash Flow Ratio

                • -4.87

                • 49.75

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -174.77

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -156.22

                        (-280.00)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -172.89

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 1.47

                      • 1.48

                      • Asset Turnover

                      • 0.12

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -16.21M
                      Operating Margin
                      -1,570.40
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -4.87
                      Ownership

                      Institutional Ownership

                      40.88%

                      Top 10 Institutions

                      40.88%

                      Mutual Fund Ownership

                      8.46%

                      Float

                      40.27%

                      5% / Insider Ownership

                      23.58%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        2,545,258

                      • 0.00

                      • 6.99

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        250,308

                      • 0.00

                      • 0.69

                      • Vanguard Total Stock Mkt Idx

                      •  

                        226,675

                      • 0.00

                      • 0.63

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        27,929

                      • 0.00

                      • 0.08

                      • Vanguard US Equity Index

                      •  

                        11,900

                      • -27.88

                      • 0.03

                      • Fidelity Spartan® Total Market Idx Fund

                      •  

                        9,973

                      • 0.00

                      • 0.03

                      • AXA/Lord Abbett Micro Cap Portfolio

                      •  

                        2,185

                      • 0.00

                      • 0.01

                      • Vanguard Extended Market Index Fund

                      •  

                        2,006

                      • 0.00

                      • 0.01

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Third Security, LLC

                      •  

                        9,839,221

                      • 0.00%

                      • 27.20

                      • Fidelity Management and Research Company

                      •  

                        2,795,566

                      • -2.48%

                      • 7.73

                      • MSDC Management, L.P.

                      •  

                        1,725,000

                      • 0.00%

                      • 4.77

                      • Vanguard Group, Inc.

                      •  

                        240,581

                      • +5.48%

                      • 0.66

                      • Janney Montgomery Scott LLC

                      •  

                        122,294

                      • +47.52%

                      • 0.34

                      • Geode Capital Management, LLC

                      •  

                        37,902

                      • 0.00%

                      • 0.10

                      • Geduld E E

                      •  

                        10,000

                      • -60.00%

                      • 0.03

                      • Columbia Management Company

                      •  

                        10,000

                      • 0.00%

                      • 0.03

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Core

                      Oragenics, Inc., was incorporated in November 1996. The Company is engaged in the discovery, development and commercialization of technologies associated with oral health, broad spectrum antibiotics and other general health benefits....more It also develop, market and sell proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. Its product candidates include: Antibiotics, Probiotic and Genetically Modified Probiotics. Antibiotics; the Company has performed preclinical testing on MU1140, a molecule belonging to the novel class of antibiotics known as lantibiotics, which has demonstrated the molecule’s novel mechanism of action. MU1140 has proven active preclinically against all Gram positive bacteria against which it has been tes...moreted, including those responsible for a number of healthcare associated infections, or HAIs. Probiotic, probiotic products contain the active ingredient ProBiora3, a patented blend of oral care probiotics that promote fresher breath, whiter teeth and support overall oral health. The Company has conducted scientific studies on ProBiora3 in order to market its products under self-affirmed Generally Recognized As Safe status GRAS. Genetically Modified Probiotics, on September 30, 2013, the Company entered into a second exclusive channel collaboration agreement with Intrexon that governs a channel collaboration arrangement in which it will use Intrexon’s proprietary technology relating to the identification, design, culturing and production of genetically modified cells, DNA vectors and in vivo control of expression for the development and commercialization of probiotics, specifically the direct administration to humans of genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus, including, but not limited to, aphthous stomatitis and Behcet’s disease. The Company face competition from nutraceutical, pharmaceutical, biopharmaceutical, medical device and biotechnology companies developing similar products and technologies both in the United States and abroad, as well as academic and research institutions, governmental agencies and private organizations engaged in drug funding or research and discovery activities both in the United States and abroad. The Company rely upon a combination of licenses, patents, trade secrets, know-how, and licensing opportunities to develop its business. The Company has developed many brand names and trademarks for its products. It uses the following unregistered trademarks: SMaRT Replacement Therapy, MU1140, IVIAT and CMAT and among others.lessless

                      Key People

                      Dr. John N. Bonfiglio, PhD

                      CEO/Director/President

                      Dr. Frederick W. Telling,PhD

                      Chairman of the Board/Director

                      Michael OKeefe Sullivan

                      CFO/Chief Accounting Officer/Secretary/Treasurer

                      Dr. Martin Handfield, PhD

                      Vice President, Divisional

                      Dr. Alan W. Dunton,M.D.

                      Director

                      • Oragenics Inc

                      • 4902 Eisenhower Boulevard

                      • Tampa, FL 33634

                      • USA.Map

                      • Phone: +1 813 286-7900

                      • Fax: +1 813 286-7904

                      • oragenics.com

                      Incorporated

                      1996

                      Employees

                      10

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: